There are 3397 resources available
Ideal duration of IT: How to define it and what are the implications
Presenter: Teresa Amaral
Session: Long term survivors in the era of immunotherapy of cancer
Resources:
Slides
Webcast
Future directions on targeted agents and beyond in thyroid and neuroendocrine tumours
Presenter: Enrique Grande Pulido
Session: Bringing together thyroid cancer and neuroendocrine tumours
Resources:
Slides
Webcast
How to treat bone, soft tissue and GIST patients with a hereditary predisposition: A medical oncologist’s perspective
Presenter: Winette Van Der Graaf
Session: Genetic predisposition in patients with sarcoma
Resources:
Slides
Webcast
What to do with stage 1 TNBC: Can we deescalate systemic therapy?
Presenter: Peter Schmid
Session: Controversies in early stage triple negative breast cancer
Resources:
Slides
Webcast
LBA59 - Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial
Presenter: Martin Reck
Session: Mini oral session 2 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
Discussion
Presenter: All Speakers
Session: Long term survivors in the era of immunotherapy of cancer
Resources:
Slides
Webcast
Discussion
Presenter: All Speakers
Session: Bringing together thyroid cancer and neuroendocrine tumours
Resources:
Slides
Webcast
How to treat sarcoma patients with a hereditary predisposition: A radiation oncologist’s perspective
Presenter: Beate Timmermann
Session: Genetic predisposition in patients with sarcoma
Resources:
Slides
Webcast
The patient's perspective and expectations
Presenter: Antonella Cardone
Session: How do we best monitor patients during follow-up?
Resources:
Slides
Webcast
Invited Discussant LBA57, 1264MO, LBA58 and LBA59
Presenter: Edward Garon
Session: Mini oral session 2 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast